The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.

Abstract excerpt

After an era of few treatment options for patients with locally advanced or metastatic gastrointestinal stromal tumor (GIST), imatinib has emerged as the standard of care and first-line treatment for these patients. Although imatinib was initially approved at the doses of 400 and 600 mg daily, results from clinical studies established 400 mg daily as the standard initial dose for the majority of advanced GIST...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Benzamides
• Share to Drug Administration Schedule
• Share to Gastrointestinal Stromal Tumors